Navigation Links
Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications
Date:5/23/2012

NEW YORK, May 23, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications

http://www.reportlinker.com/p0866960/Arthritis-Therapeutics-Market-to-2018---Novel-Oral-JAK-Inhibitors-and-Biologic-Disease-Modifying-Anti-Rheumatic-Drugs-DMARD-Will-Drive-Continued-Growth-Across-Key-Indications.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications

Summary GBI Research's new report, "Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications", provides an expert insight into the global arthritis market and market forecast until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. The report provides an in-depth analysis of the top four arthritis therapeutic indications which are osteoarthritis, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, Furthermore, it also includes the market forecasts and treatment usage patterns of these four therapeutic indications. The report also explores the competitive landscape of the top companies in the market and an analysi
'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
2. The Strong Womans Approach to Managing Rheumatoid Arthritis
3. Defect in A20 gene expression causes rheumatoid arthritis
4. Hospital for Special Surgery to Host International Arthritis Summit: Frontiers in Osteoarthritis Research, Prevention and Care
5. CrystalGenomics Initiates CG100649 Phase 2b Study in Patients with Osteoarthritis
6. Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis
7. TissueGene Initiates Patient Enrollment for a Phase II Study of TG-C for Osteoarthritis of the Knee
8. Novel ACR Hybrid Score in Rheumatoid Arthritis Applied for the First Time to Data from the RAPID 1 Study with Cimzia® (certolizumab pegol)
9. Arthritis drug could help beat melanoma skin cancer
10. Alder Biopharmaceuticals Announces That Data From Multiple Studies of ALD518 (BMS945429), an Investigational Antibody Therapeutic in Rheumatoid Arthritis Patients, to be Presented at Annual Meeting of the American College of Rheumatology
11. Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... China Biologic Products, Inc. (NASDAQ: CBPO, ... integrated plasma-based biopharmaceutical company in China ... Shandong Taibang Biological Products Co. Ltd., has received ... Food and Drug Administration (the "CFDA") for its ... in the Company,s public filings, the CFDA inspected ...
(Date:12/24/2014)... SARASOTA, Fla. , Dec. 23, 2014  Rock ... today that it has filed a Clinical Trial Application ... Medicines Healthcare products Regulatory Agency (MHRA) seeking regulatory approval ... its lead molecule, Anatabine Citrate. Contingent on ... to conduct a Phase I trial to assess the ...
(Date:12/22/2014)... 22, 2014 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: ... focused on the development of autologous cell therapies, announced ... University of Calgary in conjunction with co-authors from Kyoto ... validates the company,s ongoing clinical research using dermal sheath ... baldness. The paper entitled " Hair Follicle ...
(Date:12/22/2014)... December 22, 2014 The ... publication of original research, reviews and editorials addressing ... clinical practice, today published a provocative article exploring ... development, progression and potential treatment of prostate cancer. ... research and proposes the possibility that there could ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4
... Reports Financial Results for the 12 Months Ended December ... A/S,(OMX: GEN) announced today results for the financial year ... (approximately USD 104 million) compared to,DKK 136 million (approximately ... of DKK 437 million (approximately USD 86 million).,This compares ...
... (OTC Bulletin Board: IMYN), a biotechnology firm that ... to,the biopharmaceutical SF-1019, has announced its results for ... the year ended December 31, 2007, the company ... in interest expense which,was funded from advances by ...
... Elbit Imaging Ltd.,(Nasdaq: EMITF ) ("EI" or ... year 2007., Transition to IFRS, Through ... been,prepared in accordance with generally accepted accounting principles ... provisions of Standard 29 of the Israeli,Accounting Standard ...
Cached Biology Technology:Genmab Announces Year End 2007 Financial Results 2Genmab Announces Year End 2007 Financial Results 3Genmab Announces Year End 2007 Financial Results 4Genmab Announces Year End 2007 Financial Results 5Immunosyn Corporation Announces 2007 Results, Files 10KSB 2Immunosyn Corporation Announces 2007 Results, Files 10KSB 3Elbit Imaging Ltd. Announces Results For Fiscal Year 2007 2Elbit Imaging Ltd. Announces Results For Fiscal Year 2007 3Elbit Imaging Ltd. Announces Results For Fiscal Year 2007 4Elbit Imaging Ltd. Announces Results For Fiscal Year 2007 5Elbit Imaging Ltd. Announces Results For Fiscal Year 2007 6Elbit Imaging Ltd. Announces Results For Fiscal Year 2007 7Elbit Imaging Ltd. Announces Results For Fiscal Year 2007 8Elbit Imaging Ltd. Announces Results For Fiscal Year 2007 9Elbit Imaging Ltd. Announces Results For Fiscal Year 2007 10Elbit Imaging Ltd. Announces Results For Fiscal Year 2007 11Elbit Imaging Ltd. Announces Results For Fiscal Year 2007 12Elbit Imaging Ltd. Announces Results For Fiscal Year 2007 13Elbit Imaging Ltd. Announces Results For Fiscal Year 2007 14Elbit Imaging Ltd. Announces Results For Fiscal Year 2007 15Elbit Imaging Ltd. Announces Results For Fiscal Year 2007 16
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
(Date:12/10/2014)... 9, 2014  Wake Forest Baptist Medical Center today announced ... School of Medicine. Funding for this $50 million capital ... will be publicly launched next summer. ... former 60 series R.J. Reynolds Tobacco Company complex, adjacent ... begin immediately with plans to be ready to welcome ...
(Date:12/5/2014)... 2014  Tute Genomics, a leader in cloud-based solutions ... A1 funding led by UK-based Eurovestech. Peak Ventures and ... investment round. "We are at a pivotal ... sequencing and seeks new approaches for the diagnosis, treatment ... MD MBA, and CEO of Tute Genomics. "One of ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... University researchers have received a $1.5 million federal ... account of their ecological footprint., Seven researchers in ... Resources, Biosystems Engineering, and USDA Agricultural Research Service ... elements central to farming and out of balance ...
... purification of drug components is a large hurdle facing ... that utilize proteins, which are notoriously difficult to separate ... for Biotechnology and Interdisciplinary Studies (CBIS) at Rensselaer Polytechnic ... and improve an important protein purification process. ...
... new class of drug designed to target the hepatitis ... some of the HCV strains being treated exhibited signs ... of Florida State University biologists, chemists and biomedical researchers ... the drug-resistant HCV strains and the molecular-level mechanisms that ...
Cached Biology News:WSU researchers taking sustainability of organic farming to new level 2Purifying proteins: Rensselaer researchers use NMR to improve drug development 2Purifying proteins: Rensselaer researchers use NMR to improve drug development 3Hepatitis C virus faces new weapon from Florida State scientists 2Hepatitis C virus faces new weapon from Florida State scientists 3
GEL FILTRATION CAL KIT HMW, 1 EA. *Category: Gel Filtration Gels....
Mouse monoclonal [6C3] to JAB1 ( Abpromise for all tested applications). entrezGeneID: 10987 SwissProtID: O15386...
Human TGF-beta RIIb Affinity Purified Polyclonal Ab...
Human FGF R2 (alpha isoforms) MAb (Clone 98706)...
Biology Products: